Arthur Levin
Director/Board Member chez AVIDITY BIOSCIENCES, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Dr. Arthur A.
Levin is an Independent Director at Stoke Therapeutics, Inc. and a Director & Strategic Leader at Avidity Biosciences, Inc. He is on the Board of Directors at Stoke Therapeutics, Inc., Avidity Biosciences, Inc. and Amylon Therapeutics BV.
Dr. Levin was previously employed as an Executive Vice President-Research & Development by 358th Shelf Corp., a Senior Vice President-Development by Ionis Pharmaceuticals, Inc., a Research Leader by Hoffmann-La Roche, Inc., and a Chief Development Officer & Vice President by Roche Innovation Center Copenhagen A/S.
He also served on the board at Oligonucleotide Therapeutics Society, Inc. He received his undergraduate degree from Muhlenberg College and a doctorate degree from Rochester Christian University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AVIDITY BIOSCIENCES INC
0,34% | 19/04/2024 | 268 702 ( 0,34% ) | 7 M $ | 31/03/2024 |
STOKE THERAPEUTICS, INC.
0,04% | 01/09/2023 | 17 979 ( 0,04% ) | 242 717 $ | 31/03/2024 |
Postes actifs de Arthur Levin
| Sociétés | Poste | Début |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Director/Board Member | 23/02/2023 |
| STOKE THERAPEUTICS, INC. | Director/Board Member | 01/09/2015 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Director/Board Member | - |
Anciens postes connus de Arthur Levin
| Sociétés | Poste | Fin |
|---|---|---|
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Corporate Officer/Principal | - |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Arthur Levin
| Rochester Christian University | Doctorate Degree |
| Muhlenberg College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| STOKE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |
